HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients
Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
HBsAg Loss/Seroconversion is uncommon in Low replicative chronic HBV infection patients. The
purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg
loss/seroconversion therapy in Low replicative chronic HBV infection patients with Low Level
HBsAg.
Phase:
Phase 4
Details
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Collaborators:
First People's Hospital of Foshan First People's Hospital, Shunde China Huazhong University of Science and Technology Huizhou Municipal Central Hospital Nanchang University Peking University Shenzhen Third People's Hospital Tang-Du Hospital The First Affiliated Hospital of Kunming Medical College Yuebei People's Hospital